There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Angie Drakulich was editorial director of Pharmaceutical Technology.

Articles

Genotoxic impurities and how to identify them and control for them have been a concern for several years in the pharmaceutical manufacturing industry. Pharmaceutical Technology spoke with Bo Shen, PhD, principal scientist at Amgen and chair of the AAPS Pharmaceutical Trace Impurities Focus Group, to gain insight on key challenges.

Genotoxic Impurities: A Q&A with Amgen's Bo Shen

In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.

Evaluating Impurities in Drugs (Part II of III)

In the Spotlight March 2012

A nickel's worth of free advice to the competition could come at the expense of your bottom line.

Shipping with the Enemy?

In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.

Evaluating Impurities in Drugs (Part I of III)

Where is the variability coming from and what have we done to minimize it?

Reducing Common Cause Variation

The Asian nation is strategizing to take the lead over its regional competitors in pharmaceutical exports.

Report from India

In the Spotlight February 2012

Technology may expedite operations, but the absence of the human element could cost dearly.

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes